China Is Creating a New Master Race

 

China Is Creating a New Master Race

by Gordon G. Chang
February 10, 2021 at 5:00 am

Share976

• China Is Creating a New Master Race :: Gatestone Institute"U.S. intelligence shows that China has conducted human testing on members of the People's Liberation Army in hope of developing soldiers with biologically enhanced capabilities," wrote then Director of National Intelligence John Ratcliffe, in a December 3 Wall Street Journal op-ed titled "China Is National Security Threat No. 1."

• All these Chinese moves are meant to obtain "biological dominance." "There are," as Ratcliffe noted, "no ethical boundaries to Beijing's pursuit of power."

• The experiment evoked the eugenics program of the Third Reich to create a "master race."

• Shenzhen's He [Jenkui], after an international uproar caused by news of his dangerous and unethical work, was fined and jailed for "illegally carrying out human embryo gene-editing," but in the Communist Party's near-total surveillance state he obviously had state backing for his experiments.... Beijing's prosecution of He, therefore, looks like an attempt to cool down the furor and prevent the international scientific community from further inquiry into China's activities.

• "What is most disturbing about these endeavors is that China has gleaned access to CRISPR and advanced genetic and biotech research, thanks to their relationship with the United States and other advanced Western nations. American research labs, biotech investors, and scientists have all striven to do research and business in China's budding biotech arena... because the ethical standards for research... are so low." — Brandon Weichert, author of The Weichert Report and Winning Space, interview with Gatestone Institute, February 2021.

China's regime does not have ethics or decency, is not bound by law, and does not have a sense of restraint. However, with its rapid weaponization of biotechnology, it does have the technology to start a whole new species of genetically enhanced, goose-stepping humans. Pictured: Soldiers of the People's Liberation Army march on October 1, 2019 in Beijing, China. (Photo by Kevin Frayer/Getty Images)

Bing Su, a Chinese geneticist at the state-run Kunming Institute of Zoology, recently inserted the human MCPH1 gene, which develops the brain, into a monkey. The insertion could make that animal's intelligence more human than that of lower primates. Su's next experiment is inserting into monkeys the SRGAP2C gene, related to human intelligence, and the FOXP2 gene, connected to language skills.

Has nobody in China seen Planet of the Apes?

Or maybe they have. "Biotechnology development in China is heading in a truly macabre direction," writes Brandon Weichert of The Weichert Report in an article posted on the American Greatness website.

In a communist society with unrestrained ambition, researchers are pursuing weird science. What happens when you mix pig and monkey DNA? Chinese experimenters can tell you. How about growing human-like organs in animals? Yes, they have done that as well.

Moreover, Beijing may already be engineering "super soldiers." "U.S. intelligence shows that China has conducted human testing on members of the People's Liberation Army in hope of developing soldiers with biologically enhanced capabilities," wrote then Director of National Intelligence John Ratcliffe, in a December 3 Wall Street Journal op-ed titled "China Is National Security Threat No. 1."

It is not clear how far Chinese military researchers have gone. They are, however, advocating use of the CRISPR gene-editing tool to enhance human capabilities, and the Communist Party's Central Military Commission is "supporting research in human performance enhancement and 'new concept' biotechnology."

The People's Liberation Army has gone all-in on gene editing of humans. As leading analysts Elsa Kania and Wilson VornDick report, there are "striking parallels in themes repeated by a number of PLA scholars and scientists from influential institutions."

All these Chinese moves are meant to obtain "biological dominance." "There are," as Ratcliffe noted, "no ethical boundaries to Beijing's pursuit of power."

It is clear that the Communist Party is thinking about more than just soldiers. A Chinese researcher is also the first — and so far only — person to gene-edit human embryos that produced live births.

He Jiankui, while at Southern University of Science and Technology in Shenzhen, used the CRISPR-Cas9 tool to remove gene CCR5 to give twin girls, born in late 2018, immunity to HIV but perhaps also to enhance intelligence. The experiment evoked the eugenics program of the Third Reich to create a "master race."

China is in the process of creating the "perfect Communist," Weichert, also the author of Winning Space, told Gatestone. "China is run by a regime that believes in the perfectibility of mankind, and with the advent of modern genetic and biotechnology research, China's central planners now have the human genome itself to perfect according to their political agenda."

Chinese scientists already are on the road of "gene-doping" to make future generations smarter and more innovative than those in countries refusing to embrace these controversial methods. "What you are witnessing in China," Weichert has written, "is the convergence of advanced technology with cutting-edge bio-sciences, capable of fundamentally altering all life on this planet according to the capricious whims of a nominally Communist regime."

Shenzhen's He, after an international uproar caused by news of his dangerous and unethical work, was fined and jailed for "illegally carrying out human embryo gene-editing," but in the Communist Party's near-total surveillance state, he obviously had state backing for his experiments.

He's efforts are not isolated. Nature magazine's news team reported in April 2015 that Chinese researchers at Sun Yat-sen University in Guangzhou, in another world-first experiment, edited "non-viable" human embryos with CRISPR-Cas9. "A Chinese source familiar with developments in the field said that at least four groups in China are pursuing gene editing in human embryos," the magazine's website stated.

Beijing's prosecution of He, therefore, looks like an attempt to cool down the furor and prevent the international scientific community from further inquiry into China's activities.

Unfortunately, China's advances in gene editing human embryos for super soldiers is persuading others they must do the same. Soon, for instance, there will be "Le Terminator." The French government has just given approval for augmented soldiers. "We have to be clear, not everyone has the same scruples as us and we have to prepare ourselves for such a future," declared French Minister for the Armed Forces Florence Parly.

Michael Clarke of Kings College London told the Sun, the British tabloid, there is now a biological competition fueled by China. Will we soon have, as the International Society for Military Ethics has dubbed it, a race of "homo robocopus"?

If we do, China will not be the only party to blame. "What is most disturbing about these endeavors is that China has gleaned access to CRISPR and advanced genetic and biotech research, thanks to their relationship with the United States and other advanced Western nations," Weichert told Gatestone this month. "American research labs, biotech investors, and scientists have all striven to do research and business in China's budding biotech arena explicitly because the ethical standards for research on this sensitive issue are so low."

"This will prove to be a long-term strategic threat to the United States that few in Washington, on Wall Street, or in Silicon Valley understand," Weichert says, referring to China's rapid weaponization of biotechnology.

China's regime does not have ethics or decency, is not bound by law, and does not have a sense of restraint. It does, however, have the technology to start a whole new species of genetically enhanced, goose-stepping humans.

Gordon G. Chang is the author of The Coming Collapse of China, a Gatestone Institute Distinguished Senior Fellow, and a member of its Advisory Board.

German minister angry at vaccine rollout, which EU chief defends

 German Finance Minister Olaf Scholz said on Saturday he was angry that more COVID-19 vaccines were not ordered last year as EU chief executive Ursula von der Leyen renewed her defence of the European Commission's record on rolling them out.

FEB 06 2021

By Reuters Staff

2 MIN READ

FILE PHOTO: German Finance Minister Olaf Scholz speaks at the lower house of parliament Bundestag in Berlin, Germany, December 8, 2020. REUTERS/Michele Tantussi

BERLIN (Reuters) - German Finance Minister Olaf Scholz said on Saturday he was angry that more COVID-19 vaccines were not ordered last year as EU chief executive Ursula von der Leyen renewed her defence of the European Commission’s record on rolling them out.

EU countries have so far given first doses to just under 4% of their populations, compared with 11% for the United States and almost 17% for Britain, according to Our World in Data. Von der Leyen has been under fire for the EU’s slow rollout.

“I’m angry about some of the decisions that were taken last year,” Scholz told BBC radio’s Today programme. “I think there had been the opportunity to order more of the vaccines.”

Asked about von der Leyen’s responsibility for the slow rollout, Scholz, speaking in English, replied: “I think it is necessary that anyone learns the lesson, and this is also (true) for Europe. I think the European Union is strong.”

Scholz, a Social Democrat, and von der Leyen, a Christian Democrat, served together in Germany’s ruling coalition until 2019, when she quit to take over as European Commission president.

In an opinion piece to run in Sunday’s Frankfurter Allgemeine Sonntagszeitung, von der Leyen said it was misleading to say that sealing vaccine contracts earlier would have speeded up their delivery.

“The bottleneck lies elsewhere. Producing a new vaccine is an incredibly complex business,” she wrote, adding that “among the hundreds of components needed, important ingredients are in short supply worldwide”.

Describing the fight against the virus as “not a sprint, it is a marathon”, von der Leyen added that “mutations worry us”.

“We need to prepare today for a scenario in which the virus can no longer be sufficiently suppressed with current vaccines,” she said.

Writing by Paul Carrel; Editing by Nick Macfie

https://www.reuters.com/article/us-health-coronavirus-germany-eu-idUSKBN2A60JC

Yanis Varoufakis destroys 'glorified cartel' EU - Jab chaos exposes bloc's 'true weakness'

The former Greek finance minister blamed the vaccine disaster on a lack of democracy and the EU originating as a "glorified cartel". There is outrage across Europe at the number of vaccines acquired by the European Commission, which was put in charge of procurement.

 4 February 2021 

James Bickerton   Express

The failure of the French Sanofi vaccine to work, and a smaller than expected delivery from British-Swedish company AstraZeneca, has plunged the continent into crisis.

Mr Varoufakis said: "The EU vaccines procurement fiasco is yet further proof that inefficient bureaucracy was never the EU's true weakness

"The roots of the union's multiple failures can be traced to its origins in a glorified cartel.

"The rules that have caused so much avoidable pain across the continent, and have guaranteed the oligarchy immunity from anything resembling a democratic process, are embedded in the unwritten corporatist covenant at the centre of the EU.

© GETTY Coronavirus

"Unlike nation-states that emerge as stabilisers of conflicts between social classes and groups, the EU was created as a cartel with a remit to stabilise the profit margins of the large, central European corporations.

"We also know that, unlike proper states, cartels will resist any democratisation of their decision-making, whether it is about debt or vaccines."

Last week the EU caused global outrage by threatening to stop vaccine exports from the bloc and reimpose a hard-border between Ireland and Northern Ireland to block a potential backchannel into the UK.

Following fury in London, Dublin and Belfast the EU was forced to back down.

It was also criticised by the World Health Organisation which warned Brussels could unleash a wave of Covid vaccine protectionism.

Mr Varoufakis argued the EU's vaccine procurement policy was undermined by political considerations.

Writing in the New Statesman, he said: "The European Commission's policy for ordering vaccines was driven by one imperative: to keep the Franco-German axis in balance.

"Why else did Brussels split the lion's share of the EU's vaccine budget straight down the middle between German company BioNTech and French company Sanofi (placing an order for 300 million vaccines from each), while procrastinating for three months over the Brexit-tainted AstraZeneca vaccine?

"When the French vaccine was significantly delayed in clinical trials, leaving the Commission with a serious vaccine shortage, the panicked reaction came straight out of the euro crisis book of malice.

"The EU lashed out by threatening to impose a 'vaccine border' on the island of Ireland, exposing the mendacity of its professed commitment to the Good Friday Agreement."

Mr Varoufakis, an economist, served as Greek Minister of Finance from January to July 2015.

© EXPRESS Coronavirus

During this time he helped lead Greece's negotiations with its creditors during the Eurozone crisis.

He resigned after the Greek government decided it had to make concessions to Brussels.

Mr Varoufakis argued the coronavirus crisis has again exposed the inflexibility of EU institutions.

He commented: "Together, EU officials and the oligarchs of Europe's south and north have contrived to rob European peoples, both in sickness and in health, of any capacity to participate in the decision-making process.

"As a result, 13 years after the 2008 crisis, the pandemic has hardened the reality of Europe as the world's richest and at once sickest continent.

"They have done so by turning the EU into a cash cow that must be at once submitted to unquestioningly and blamed by our domestic oligarchies for their failures."

https://www.msn.com/en-gb/news/world/yanis-varoufakis-destroys-glorified-cartel-eu-jab-chaos-exposes-blocs-true-weakness/ar-BB1dnjTh

READ MORE: EU humiliated as bloc 'keeping members equally discontented'

DON'T MISS

Gove explodes at EU as bloc accused of breaking Brexit deal trust [SHOCK]

Take that Brussels! Finland follows UK's lead on vaccine dosage [REVEAL]

Switzerland bans AstraZeneca vaccine for ALL citizens [INSIGHT]

Countdown to 'catastrophe:' Inside Europe's fight for COVID shots

 BRUSSELS (Reuters) - In a meeting last week in the Europa building in Brussels, home of the European Union’s political leadership, diplomats for the 27 member states were desperate.

FEBRUARY 5, 2021

By Francesco Guarascio, John Chalmers

FILE PHOTO: A view shows a meeting room in Europa, the new European Council building in Brussels, Belgium December 9, 2016. Building: Philippe Samyn and Partners architects & engineers, lead and design partner, Studio Valle Progettazioni architects, BuroHappold engineers; colour compositions by Georges Meurant. REUTERS/Yves Herman

The EU had paid billions of euros toward shots to curb a pandemic that was killing thousands of Europeans every day. Now vaccine-makers had cut back deliveries, and the EU was trapped in a public fight.

“This is a catastrophe,” French ambassador Philippe Leglise-Costa told the Jan. 27 meeting, according to a diplomatic note seen by Reuters.

It was a crucial moment in nearly two weeks of confusion and anger over the EU’s vaccine supply, which were to plunge the bloc into its deepest crisis since Ursula von der Leyen took over the executive European Commission just over a year ago.

A week earlier, the EU had set a target to vaccinate 70% of adults against COVID-19 by the end of summer, a potential ticket out of lockdowns that have cost countries billions. As the impact of the vaccine shortfall became clear, the bloc embarked on a campaign to shame drugmakers hit by production delays into releasing more supply.

But the tactic wasn’t working and details of confidential deals were leaking out, casting doubt on the EU’s ability to enforce contracts it had agreed on behalf of its members.

Reuters has obtained exclusive details of internal EU talks over the past month in diplomatic notes, and interviewed four people present at key meetings to verify them. The notes reveal how the EU’s top executives lurched from satisfaction about the vaccination programme to panic.

Some EU officials were already aware in December of delays in vaccine production, the notes show, but the Commission announced ambitious targets nonetheless. The EU initially kept no track of companies’ vaccine doses leaving the bloc, only realising after its own supplies were delayed it could not trace the millions of doses that had already been exported. And as its attempts to win ground by legal means failed, the Commission faced sharp attacks from EU governments on its public communication strategy.

In a pandemic that has killed over 700,000 people in Europe alone, the delays announced by the companies producing coronavirus vaccines - AstraZeneca PLC and Pfizer Inc. - risked leaving millions in Europe unprotected deep in the winter, just as new, more transmissible, variants were circulating and hospitals were being overwhelmed. Vaccination centres from Madrid to Paris had closed for lack of supply.

The EU Commission declined comment for this story. So did AstraZeneca, which has said it is focused on boosting supplies to the bloc after the manufacturing glitches. The Commission has often said it expects an exponential increase in the availability of vaccines from April. Pfizer’s Chief Executive Albert Bourla told Reuters production is back on track in Europe after the company made changes at its Belgian manufacturing site to increase supply.

The vaccine squeeze was not just a public health nightmare. It was also a political crisis.

Britain, freshly divorced from the EU’s single market after five years of bitter negotiations, was inoculating people at a much faster pace than any EU country, public data show.

Diplomats feared the Commission was losing the battle against a “narrative of ... big failure,” a senior EU diplomat who was present at the Jan. 27 meeting told Reuters. They urged the Commission to cool a row with British company AstraZeneca for the sake of getting drugs as soon as possible, the notes show and people present said.

The Commission’s dilemma underscores the power of big drugmakers as governments scramble to vaccinate their citizens, and the geopolitical tensions that can result.

Eventually, the notes show EU diplomats recognised the bloc may not benefit from arguing about contracts with AstraZeneca. Instead, the Commission turned up the heat on the United Kingdom - which AstraZeneca said was preventing British-made vaccines from reaching Europe - only to swiftly step back after realising it risked disrupting a border agreement in the Brexit accord which London and Dublin said could have serious consequences for security in Northern Ireland.

The damage to the EU’s image was visible on the front pages of Britain’s eurosceptic popular press, with headlines declaring “EU vaccines war explodes” and “EU chiefs behaving like the mafia.”

A spokesman for the French ambassador said he had urged the EU “to communicate in an orderly and strategic manner.”

A British government spokesperson said, “We are in constant contact with the vaccine manufacturers and remain confident that the supply of vaccine to the UK will not be disrupted.” The UK government declined to comment on AstraZeneca’s claim it was preventing vaccines from reaching Europe, but said it does not prohibit any export of COVID-19 vaccines.

“GLITCH-FREE”

The month started calmly for member states, who had agreed at the start of the pandemic to form a steering group with the EU executive to negotiate with drugmakers, to support smaller states and prevent internal squabbling.

EU Commission officials and diplomats involved met in the Europa Building’s S7 Room, a windowless chamber where delegates assembled at a round table beneath a ceiling decorated with dozens of squares in pastel colours. The Commission was represented by the EU’s top vaccine negotiator, Sandra Gallina, an Italian national who started working for the EU Commission more than three decades ago as an interpreter. She declined to comment for this story.

The EU was about three weeks behind Britain in launching a vaccine - largely because it opted against issuing emergency regulatory approval as Britain had done. But the EU had announced deals with six vaccine-makers to secure nearly 2.3 billion doses for its population of 450 million.

Pfizer, working with German partner BioNTech, was one of only two firms whose shots had approval. It was the only one supplying the EU, which had announced deals for up to 600 million Pfizer doses. The roll-out began immediately after Christmas.

“Deliveries are so far mostly glitch-free,” Gallina told diplomats in a Jan. 8 briefing, according to a note from the meeting.

Gallina told the briefing the EU was receiving 3.5 million doses of the Pfizer vaccine a week. She underscored that the UK, by contrast, had reserved only 4 million doses of the Pfizer shot until February. Pfizer declined to comment, saying delivery schedules are confidential.

Gallina told diplomats some countries were passing on their share of Pfizer doses in anticipation of securing drugs from AstraZeneca, which was due to launch deliveries to the EU once its vaccine won regulatory approval there in late January. Both companies’ vaccines are made and exported from plants a short drive from Brussels. AstraZeneca also makes vaccines for the EU at factories in Germany and Britain, according to the EU Commission.

Gallina told the meeting member states saw AstraZeneca as a “star” for its low prices and big numbers.

The companies have declined to comment on prices; AstraZeneca’s vaccine costs about 2.5 euros ($3) per dose, against 15.5 euros for Pfizer’s, two EU negotiators directly involved in talks with vaccine makers told Reuters. AstraZeneca committed to deliver at least 80 million doses through March, or up to 120 million, an official involved in the talks told Reuters.

EU negotiators were aware AstraZeneca was scaling back its planned supply because of production problems. The company had told the EU’s steering group on Dec. 4 that it would reduce its targets for the first quarter to two-thirds of the 120 million maximum, according to a diplomatic note.

At a public hearing on Jan. 12 in the European Parliament, Gallina told EU lawmakers that she had heard only three instances of “relatively minor” complaints about deliveries.

REALITY CHECK

Three days later, on Jan. 15, Pfizer too said it had trimmed production and would temporarily cut supplies to the EU from its Belgian plant. There was an immediate public outcry across Europe. Italy’s special commissioner for COVID-19, Domenico Arcuri, said Italy was considering legal action against Pfizer.

Despite these delays, the EU Commission went ahead and announced an ambitious vaccination goal.

On Jan. 19, when just over 5 million vaccines had been administered in the EU, the Commission published targets to inoculate at least 80% of health workers and the elderly above the age of 80 by March, and 70% of the EU’s adult population by the end of the summer. It also proposed a way to donate excess doses to poorer countries.

The next day in the S7 Room briefing, EU diplomats told Commission officials those goals were too bold.

“We have only about 2% vaccinated. How did you come up with the 70% target?” a representative from Lithuania asked. “We prefer to under-promise and over-deliver,” the Dutch delegate said. A spokesman for the Dutch ambassador confirmed the Netherlands had raised concerns about the ambition in the Commission proposal. A spokeswoman for the Lithuanian ambassador declined to comment.

Three days later, the notes showed Gallina telling diplomats that Pfizer’s sudden cut had “savaged” member states’ vaccination plans. But she reassured them shipments would resume the following week.

“SHOCKED”

Worse was to come. On Friday Jan. 22, AstraZeneca, due to start EU deliveries on Feb. 15, said it would cut supplies further over the first three months. A senior official involved in the talks told Reuters this would mean a roughly 60% fall - to 31 million doses instead of 80 million.

The European Commission went on the offensive. A few hours after the announcement, Health Commissioner Stella Kyriakides tweeted about her “deep dissatisfaction.” The following Monday the Commission summoned AstraZeneca’s executives to meetings to pressure the company to lift deliveries.

The Commission won concessions - AstraZeneca sweetened its offer to add 8 million doses from an earlier date of Feb. 7.

It was not enough. Aware of production problems at AstraZeneca’s Belgian site, the EU Commission asked for drugs from Germany and Britain. But AstraZeneca offered no clarity on whether doses could be diverted from Britain, an EU official who attended the meeting said.

The next day, the company’s Chief Executive Pascal Soriot told European newspapers AstraZeneca was not legally required to deliver doses to the EU on a precise timeline, because its contract only stated it would make its “best efforts” to deliver.

He also said Britain had signed up for its vaccine earlier than the EU and had asked to be served first from UK-based plants. The UK government declined to comment.

Soriot’s remarks infuriated the EU Commission. On Jan. 27, according to the notes, Gallina told diplomats she was “shocked” by “the level of incorrect statements” that she said Soriot had made about AstraZeneca’s commitments. AstraZeneca declined to comment.

The Commission, saying it was confident of the strength of its legal arguments, publicly demanded AstraZeneca publish the contract they had agreed. A heavily redacted version was eventually made public on Jan. 29.

“BACK AGAINST THE WALL”

At the Jan. 27 meeting, Gallina told delegates around the S7 Room table that some of the problems with AstraZeneca had already been known, but the new cut was “a big blow.”

She also said the EU had no breakdown of who was exporting vaccines where. “We have some information but we need more,” she said.

Rough customs data showed millions of COVID-19 vaccines had been exported in past weeks from the EU to Britain, Canada, Israel and China, she said. The EU Commission did not respond to a request for export data. Britain, Israel and Canada have said they received Pfizer’s vaccines from the EU; Britain has also said it received AstraZeneca’s vaccine from the EU. Fosun, the China-based company which has exclusive rights to sell Pfizer’s vaccine in China and Hong Kong, had no comment.

Gallina added the EU would set up a new mechanism to track and licence exports. The EU’s lawyers could use several legal arguments to pressure AstraZeneca into releasing more doses, she added.

The briefing did not go well. At least five diplomats told the meeting the Commission had pushed too far in its public fight and urged it to calm the dispute, at least privately. Legal action would not produce more vaccines quickly, they said.

“The Commission has its back against the wall,” French ambassador Leglise-Costa told the meeting, according to the notes. He urged an immediate change in the communication strategy.

Later that day, on another call with the Commission, Soriot told the EU not to expect doses from AstraZeneca’s factories in Britain because London was using a clause in its contract that gave it priority over doses made in the United Kingdom, two EU officials told Reuters.

“ACT OF HOSTILITY”

Seeing that diplomats wanted to tone down the fight with AstraZeneca, the Commission set its sights on Britain’s government.

The next day, EU officials publicly threatened to block vaccine exports - a move likely to hit Britain’s imports of vaccines from Pfizer’s Belgian plant. And the Commission said it wanted to set up a mechanism that would require companies to seek authorisation before exporting vaccine doses.

On Friday Jan. 30, it took a further step, threatening to trigger a clause that would block vaccines from reaching Northern Ireland - a British-run province that remained part of the EU internal market after the Brexit divorce.

Imposing restrictions on that border was potentially explosive: The Brexit talks had agreed to keep it open, to preserve the central plank of a 1998 peace deal ending 30 years of armed conflict in the province.

Northern Ireland’s First Minister Arlene Foster called the EU proposal “an incredible act of hostility,” and EU officials soon admitted it was excessive.

By Sunday, the Commission had retreated on both fronts.

Commission President Von der Leyen announced in a tweet the bloc had achieved a “step forward on vaccines.” AstraZeneca had offered to increase deliveries, she said.

After a week of fighting and diplomatic confusion, the EU had secured just 1 million doses more than the firm’s initial sweetened offer, her tweet revealed.

Additional reporting from Michael Erman in New York, Emilio Parodi in Milan, Giselda Vagnoni in Rome, Maria Sheahan in Berlin, Ludwig Burger in Frankfurt, Steve Scheer in Jerusalem, Costas Pitas and Alistair Smout in London, Roxanne Liu in Beijing, Miyoung Kim in Seoul; Edited by Sara Ledwith and Michele Gershberg

Our Standards: The Thomson Reuters Trust Principles.

MORE FROM REUTERS

https://www.reuters.com/article/us-health-coronavirus-vaccines-europe-in/countdown-to-catastrophe-inside-europes-fight-for-covid-shots-idUSKBN2A50I1